ClinicalTrials.gg

Program

brelovitug

Also written as “Brelovitug 300 mg”, “Brelovitug 900 mg” and “Brelovitug (BJT-778)”.

Its studies are mostly in Hepatitis D · Hepatitis D, Chronic, led by Mirum Pharmaceuticals.

Furthest: phase 3, since Mar 26, 20254 company-led studies, 4 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mirum Pharmaceuticals44 open or runningphase 3since Mar 26, 2025Mar 26, 2025Jun 30, 2027phase 3 · NCT07200908

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2025First study: phase 3 study in Hepatitis DFirst studyNCT06907290 · 150 enrolled · United States, Australia, Bulgaria and more
  2. Sep 16, 2025Phase 3 study in Hepatitis DNCT07200908 · 172 planned · Austria, Czechia, France and more
  3. Dec 19, 2025Phase 3 study in Hepatitis DNCT07298330 · 80 enrolled · United States, Belgium, Bulgaria and more
  4. Mar 2, 2026Phase 3 study in Hepatitis D, ChronicNCT07454837 · 120 planned · Austria, Czechia, France and more

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Hepatitis DNCT07200908
  2. Aug 31, 2027Primary completion: phase 3 study in Hepatitis D, ChronicNCT07454837
  3. May 2029Primary completion: phase 3 study in Hepatitis DNCT06907290

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07454837Hepatitis D, Chronic · Austria, Czechia, France and more3RecruitingAug 31, 2027120
NCT07298330Hepatitis D · United States, Belgium, Bulgaria and more3Active, not recruitingAug 202680
NCT07200908Hepatitis D · Austria, Czechia, France and more3RecruitingJun 30, 2027172
NCT06907290Hepatitis D · United States, Australia, Bulgaria and more3Active, not recruitingMay 2029150

How it is read

Names in the registry

  • “Brelovitug 300 mg”, 3 entries
  • “Brelovitug 900 mg”, 2 entries
  • “Brelovitug (BJT-778)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.